Grants4Apps Accelerator and new Dealmaker now open for submissions

The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.

Grants4Apps Accelerator Berlin 2017

Startups receive € 50,000 each as well as office space in the Bayer Pharmaceuticals Headquarters. Additionally, C-level mentors will support in refining business models, validating technologies and more.

The Grants4Apps team is looking for startups with innovative healthcare solutions. The team is open for any healthcare topics and will give special attention to Bayer-relevant focus areas. This year Grants4Apps is focusing on digital health solutions in the areas of Nephrology (e.g., Chronic Kidney Disease), Women's Health (e.g., Endometriosis), Pulmonology (e.g., Pulmonary Hypertension), Cardiology (e.g., Atrial Fibrillation), Hematology, Oncology, Radiology, Infectious Diseases and Ophthalmology (e.g., Diabetic Retinopathy).

Grants4Apps is also calling for collaboration projects using software or hardware to be applied in clinical trials and medical IT using state-of-the art-technologies such as artificial intelligence, machine learning, deep learning, sophisticated algorithms, bioinformatics, genomics analysis, novel approaches for Electronic Health Records (EHR) etc. - in short: highly innovative technologies with a taste for excellent simplicity and unbeatable user experience focus.

Submission deadline: 31 May 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/accelerator-berlin-2017/

Dealmaker Berlin 2017

Don't need acceleration? Want to gain Bayer as a potential customer? Then this is for you! Mature startups can apply to solve specific 'Bayer challenges'. The top startup matches will have the opportunity to come to Berlin in September (travelling costs will be covered by Bayer) and to sign a potential project deal, please find the challenge you can solve.

If there is a match, you will be inviteed to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Applicants are asked to address one or multiple challenges. However, the Dealmaker is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...